NASDAQ:HCM HUTCHMED (HCM) Stock Price, News & Analysis $12.06 +0.16 (+1.30%) As of 01:56 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About HUTCHMED Stock (NASDAQ:HCM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HUTCHMED alerts:Sign Up Key Stats Today's Range$11.72▼$12.1350-Day Range$11.91▼$15.7452-Week Range$11.72▼$19.50Volume33,909 shsAverage Volume35,195 shsMarket Capitalization$2.10 billionP/E RatioN/ADividend YieldN/APrice Target$16.88Consensus RatingHold Company Overview HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market. HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer. Its clinical pipeline features both small molecules and monoclonal antibodies targeting receptor tyrosine kinases, immuno-oncology checkpoints and novel pathways, with ongoing trials in the United States, Europe and Asia. The company has established strategic partnerships and licensing collaborations with leading global pharmaceutical and biotechnology firms to co-develop and co-commercialize its assets. Founded in 2000 as Hutchison MediPharma and rebranded as HUTCHMED in 2018, the company is headquartered in Hong Kong, with research and development centers in Shanghai and Suzhou, China. HUTCHMED maintains commercial operations across mainland China and extends its clinical research infrastructure to the United States and Europe. Guided by an experienced leadership team with backgrounds in drug discovery, clinical development and commercial strategy, HUTCHMED continues to pursue its goal of delivering innovative medicines to patients worldwide.AI Generated. May Contain Errors. Read More HUTCHMED Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreHCM MarketRank™: HUTCHMED scored higher than 71% of companies evaluated by MarketBeat, and ranked 223rd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingHUTCHMED has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 strong buy rating, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside PotentialHUTCHMED has a consensus price target of $16.88, representing about 39.9% upside from its current price of $12.07.Amount of Analyst CoverageHUTCHMED has only been the subject of 2 research reports in the past 90 days.Read more about HUTCHMED's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth126.83% Earnings GrowthEarnings for HUTCHMED are expected to grow by 126.83% in the coming year, from $0.41 to $0.93 per share.Price to Book Value per Share RatioHUTCHMED has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about HUTCHMED's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.15% of the float of HUTCHMED has been sold short.Short Interest Ratio / Days to CoverHUTCHMED has a short interest ratio ("days to cover") of 8.84.Change versus previous monthShort interest in HUTCHMED has recently decreased by 16.24%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHUTCHMED does not currently pay a dividend.Dividend GrowthHUTCHMED does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.13 News SentimentHUTCHMED has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for HUTCHMED this week, compared to 2 articles on an average week.Search Interest2 people have searched for HCM on MarketBeat in the last 30 days. MarketBeat Follows1 people have added HUTCHMED to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, HUTCHMED insiders have not sold or bought any company stock.Percentage Held by Insiders3.60% of the stock of HUTCHMED is held by insiders.Percentage Held by Institutions8.82% of the stock of HUTCHMED is held by institutions.Read more about HUTCHMED's insider trading history. Receive HCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HCM Stock News HeadlinesInnovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally ...20 minutes ago | uk.finance.yahoo.comHUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally ...20 minutes ago | markets.businessinsider.comThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.May 21 at 1:00 AM | American Alternative (Ad)HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell CarcinomaMay 21 at 6:00 AM | globenewswire.comAward-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) SuitesMay 20 at 10:00 AM | globenewswire.comAnalysts Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Target Price at $16.88May 19 at 4:53 AM | americanbankingnews.comAward-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) PlatformsMay 18 at 10:00 AM | globenewswire.comChengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutationsMay 13, 2026 | globenewswire.comSee More Headlines HCM Stock Analysis - Frequently Asked Questions How have HCM shares performed this year? HUTCHMED's stock was trading at $13.33 at the start of the year. Since then, HCM shares have decreased by 9.5% and is now trading at $12.0650. How were HUTCHMED's earnings last quarter? HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) issued its quarterly earnings results on Friday, March, 6th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $2.50 by $2.49. The business had revenue of $135.42 million for the quarter, compared to the consensus estimate of $290.50 million. Read the conference call transcript. When did HUTCHMED IPO? HUTCHMED (HCM) raised $100 million in an initial public offering (IPO) on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities served as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers. Who are HUTCHMED's major shareholders? Top institutional investors of HUTCHMED include AIA Group Ltd (0.17%), Amundi (0.13%), Renaissance Technologies LLC (0.08%) and XY Capital Ltd (0.03%). How do I buy shares of HUTCHMED? Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HUTCHMED own? Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), GE Aerospace (GE) and ServiceNow (NOW). Company Calendar Last Earnings3/06/2026Today5/21/2026Next Earnings (Estimated)8/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 3 days ago, HCM's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HCM CIK1648257 Webwww.chi-med.com Phone852-2121-3888Fax852-2128-1778Employees1,796Year Founded2000Price Target and Rating Average Price Target for HUTCHMED$16.88 High Price Target$20.00 Low Price Target$13.75 Potential Upside/Downside+41.2%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.05 Current Ratio4.96 Quick Ratio4.83 Sales & Book Value Annual Sales$548.51 million Price / Sales3.80 Cash Flow$2.67 per share Price / Cash Flow4.47 Book Value$7.17 per share Price / Book1.67Miscellaneous Outstanding Shares174,470,000Free Float168,186,000Market Cap$2.09 billion OptionableNot Optionable Beta0.31 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:HCM) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
